Reset filter
Palavras-chave
Aritmie cardiache ×
Mostrar mais Palavras-chave
Índice
  1. 1. Klinisk studie
  2. 2. Rutindokumentation
  3. 3. Register- och kohortstudier
  4. 4. Kvalitetssäkring
  5. 5. Datastandard
  6. 6. Frågeformulär för patienter
  7. 7. Medicinsk specialitet
Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

19 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

dbGaP phs000827 N.C. Clinical Genomic Evaluation by NextGen Exome Sequencing (NCGENES) - Eligibility

- 2024-03-04 - 5 Formulários, 1 Grupo de itens, 8 Elementos de dados, 1 Idioma
Grupo de itens: IG.elig
Principal Investigator: James P. Evans, MD, PhD, University of North Carolina, Chapel Hill, NC, USA MeSH: Genetic Diseases, Inborn,Neoplasms,Adenomatous Polyposis Coli,Microcephaly,Aortic Aneurysm, Thoracic,Peripheral Nervous System Diseases,Cardiomyopathies,Leukodystrophy, Globoid Cell,Seizures,Mitochondria,Inflammation,Autoimmune Diseases,Progeria,Retina,Muscular Diseases,Rhabdomyolysis,Arrhythmias, Cardiac,Osteochondrodysplasias,Intellectual disability,Autistic Disorder,Neuromuscular Diseases,Paraplegia,Central Nervous System Diseases,Cholestasis,Anemia,Genetic Testing https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000827 North Carolina Clinical Genomic Evaluation by Next-generation Exome Sequencing This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. Participants are patients who were either seen in the UNC Cancer and Adult Genetics Clinic or referred to the study by their physician. They will be approached by their physician or a genetic counselor for recruitment. Once enrolled, a clinical geneticist or genetic counselor will obtain consent and collect blood samples to be analyzed using WES. Results may include information related to a diagnosis and incidental information. Medically actionable incidental findings will be CLIA-certified and returned to participants in a routine genetic counseling session, along with diagnostic findings. Eligible adult participants will be randomized to have the opportunity to choose to get certain types of non-medically actionable incidental findings, as well. Their decisions will be investigated, as will psychosocial and behavioral responses to sequencing and receiving sequencing information. This is a longitudinal, mixed methods study (i.e., multiple assessments pre- and post-return of results, with both quantitative and qualitative methods used to gather data). Because only the quantitative component of the study uses randomization, only measures and procedures associated with that component are included here. The third study release includes data of additional n=189 subjects.

pht004472.v3.p1

1 Grupo de itens 7 Elementos de dados

pht004469.v3.p1

1 Grupo de itens 5 Elementos de dados

pht004470.v3.p1

1 Grupo de itens 5 Elementos de dados

pht004471.v3.p1

1 Grupo de itens 7 Elementos de dados

dbGaP phs001211 NHLBI TOPMed - NHGRI CCDG: Atherosclerosis Risk in Communities (ARIC) - Eligibility

- 2023-05-17 - 4 Formulários, 1 Grupo de itens, 5 Elementos de dados, 1 Idioma
Grupo de itens: IG.elig
Principal Investigator: Eric Boerwinkle, PhD, Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA MeSH: Cardiovascular Diseases,Thromboembolism,Venous Thromboembolism,Arrhythmias, Cardiac,Atrial Fibrillation https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001211 Participants from the Atherosclerosis Risk in Communities (ARIC) Study, a large population-based longitudinal cohort study, have been included in this Project and whole genome sequencing will be performed to contribute to analyses of early-onset atrial fibrillation and venous thromboembolism. Additional phenotype and genotype data are available for these individuals on dbGaP and can be accessed through the parent ARIC Cohort accession (phs000280). The National Heart, Lung and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) program is designed to generate scientific resources to enhance understanding of fundamental biological processes that underlie heart, lung, blood and sleep disorders (HLBS). It is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program seeks to uncover factors that increase or decrease the risk of disease, identify subtypes of disease, and develop more targeted and personalized treatments. The Whole Genome Sequencing (WGS) Project is part of NHLBI's TOPMed program and serves as an initial step for the larger initiative.

pht005755.v4.p3

1 Grupo de itens 2 Elementos de dados

pht005757.v3.p3

1 Grupo de itens 12 Elementos de dados

pht005754.v4.p3

1 Grupo de itens 4 Elementos de dados

dbGaP phs000495 The Gene Partnership (TGP) - eMERGE Data - Eligibility

- 2022-12-13 - 5 Formulários, 1 Grupo de itens, 7 Elementos de dados, 1 Idioma
Grupo de itens: IG.elig
Principal Investigator: Isaac S. Kohane, MD, PhD, Boston Children's Hospital, Boston, MA, USA MeSH: Autistic Disorder,Heart Defects, Congenital,Asthma,Attention Deficit Disorders,Diabetes Mellitus, Type 1,Diabetes Mellitus, Type 2,Epilepsy,Gastrointestinal Diseases,Hypersensitivity,Autoimmune Diseases,Hematologic Diseases,Neoplasms,Arrhythmias, Cardiac,Chromosome Aberrations,Congenital Abnormalities,Dermatology,Developmental Disabilities,Endocrine System,Otolaryngology,Syndrome,Urogenital System,Hearing Loss,Immune System Diseases,Musculoskeletal Abnormalities,Nervous System Diseases,Neuromuscular Diseases,Metabolic Diseases,Nutrition Disorders,Vision Disorders,Mouth Diseases,Mental Disorders,Kidney Diseases,Respiration Disorders,Thyroid Diseases,Vascular Diseases https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000495 The Gene Partnership (TGP) is a prospective longitudinal registry at Boston Children's Hospital (BCH) to study the genetic and environmental contributions to childhood health and disease, collect genetic information on a large number of children who have been phenotyped, and implement the Informed Cohort and the Informed Cohort Oversight Board (ICOB). The term "*The Gene Partnership*" reflects a partnership between researchers and participants. Children seen at BCH are offered enrollment, as are their parents and siblings. DNA is collected on all enrollees. BCH has a comprehensive EMR system, and virtually all inpatient and outpatient data are captured electronically. Clinical data in the BCH EMR is loaded in the i2b2 data warehouse which is available to investigators. Cases, phenotypes, and covariates are ascertained using the i2b2 database. Participants at BCH in TGP have consented to receive any research result and/or incidental finding that arises from studies using TGP that is approved by the Informed Cohort Oversight Board (ICOB) and is in accordance with the participants' preferences; results are returned through the Personally Controlled Health Record (PCHR). BCH and Cincinnati Children's Hospital Medical Center (CCHMC) have partnered as the *P*ediatric *A*lliance for *G*enomic and *E*lectronic Medical Record (EMR) *R*esearch (*PAGER*) site for the eMERGE Phase II network for pediatric institutions, and the cohort for eMERGE at BCH is TGP.

pht002864.v1.p1

1 Grupo de itens 4 Elementos de dados

pht002865.v1.p1

1 Grupo de itens 5 Elementos de dados

pht002866.v1.p1

1 Grupo de itens 42 Elementos de dados

pht002867.v1.p1

1 Grupo de itens 4 Elementos de dados

Eligibility NCT00729703 Tachycardia - Eligibility

- 2021-09-20 - 1 Formulário, 2 Grupos de itens, 23 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00729703

Eligibility NCT00729235 Biventricular Tachycardias - Eligibility

- 2021-09-20 - 1 Formulário, 2 Grupos de itens, 15 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00729235

Eligibility NCT00787683 Ventricular Arrhythmia - Eligibility

- 2021-09-20 - 1 Formulário, 2 Grupos de itens, 14 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00787683

Eligibility DRKS00009676 NCT00324662 Tachyarrhythmia - Eligibility

- 2021-09-20 - 1 Formulário, 2 Grupos de itens, 10 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00321620

Eligibility NCT00680550 Atrial Fibrillation - Eligibility

- 2021-09-20 - 1 Formulário, 2 Grupos de itens, 6 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00680550

Collaborative Research Center | Transregio 240 (Sonderforschungsbereich Transregio 240) - Arrhythmia

- 2020-10-01 - 1 Formulário, 3 Grupos de itens, 8 Elementos de dados, 1 Idioma
Grupos de itens: Patient-ID, Diagnostic analysis: cardiac symptoms, Course of treatment
A central patient cohort within the interdisciplinary Collaborative Research Center / Transregio 240 aims to examine the role and function of platelets in different vascular diseases. In this questionnaire specific items on arrhythmia patients are collected.

Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation - Eligibility

- 2017-06-06 - 1 Formulário, 2 Grupos de itens, 9 Elementos de dados, 2 Idiomas
Grupos de itens: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00255281

Input Data Elements CDSS Cardial Arrythmia Tisdale 2014

- 2016-10-13 - 1 Formulário, 1 Grupo de itens, 34 Elementos de dados, 1 Idioma
Grupo de itens: Risk factors
Input Data Elements CDSS for Cardial Arrythmia: QTc Prolongation, Torsade-de pointes to evaluate the effectiveness of a CDSS for reducing the risk of QT interval prolongation in hospitalized patients. Published by Tisdale et al. 2014

Arrhythmia (Atrial and Ventricular) Protocol PhenX Toolkit

- 2016-04-26 - 1 Formulário, 1 Grupo de itens, 9 Elementos de dados, 1 Idioma
Grupo de itens: Items
Measure to assess presence of arrhythmias through collection of personal history, treatments and procedures, medication usage, and administration of an electrocardiograph (ECG). ODM derived from: https://cde.nlm.nih.gov Primary source: https://www.phenxtoolkit.org/ Recent publication: Hendershot, T., Pan, H., Haines, J., Harlan, W.R., Marazita, M.L., McCarty, C.A., Ramos, E.M., and Hamilton, C.M. (2015) Using the PhenX toolkit to add standard measures to a study. Curr. Protoc. Hum. Genet. 86:1.21.1-1.21.17. doi: 10.1002/0471142905.hg0121s86 Permission to publish granted by Carol M. Hamilton.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial